API issues are affecting the production of semaglutide products involving Torrent Pharmaceuticals and Dr. Reddy’s Laboratories.
1 report, 1 independent
Updated Sep 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
API issues are affecting the production of semaglutide products involving Torrent Pharmaceuticals and Dr. Reddy’s Laboratories.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Torrent Pharmaceuticals
Indian multinational pharmaceutical company
Nothing else this week.
- FDA
Related events
- A product was launched in the U.S. market following FDA involvement.
- Two formats of semaglutide are now competing in the weight loss market following the approval of oral semaglutide.
- The FDA is ending compounding grace periods as competition intensifies and Lilly faces pipeline setbacks in the GLP-1 market.
- FDA seeks to ease market restrictions while consumer companies Ferrara and Hershey innovate in premium product lines.
- The FDA has begun investigating online sales of toxic products.